Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.
Carcinoma, Basal Cell
DRUG: Imiquimod 5% cream
post-treatment biopsy, post-treatment biopsy
This is a prospective study including patients presenting in aggregate primary lesions affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2 mm punch) at the commencement of this study. All were submitted to a local treatment with Imiquimod 5% cream (Aldara Â®), once daily, 5 days per week for 8-16 weeks (average). All subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of treatment, and all of them were monitored monthly up to now.If positive biopsy (residue tumor) cases will managed with surgery.